课题基金 / 基金详情

项目摘要

项目成果

DAVID D HURD的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): This Ul0 application is in support of the CALGB Cooperative Group Clinical Trials conducted through the Wake Forest University School of Medicine (WFUSM) and its affiliate Members. WFUSM has been continuously awarded a CALGB U10 Grant for 45 years (CA03927) as the key support of the infrastructure for data management, the required administrative interactions with our Affiliate Members, and for the support of scientific and administrative contributions to CALGB. In addition to support for the Main Member, this U10 Grant supports the oversight of activity at our two current Affiliate Members, East Carolina University, Greenville, North Carolina and Carolina Oncology Associates of Salisbury, Salisbury, North Carolina. The specific aims of this grant application are: * To increase our scientific contributions to Disease and Modality Committee activities * To enhance the participation of our clinical research investigators through the development of pilot data at the Comprehensive Cancer Center of Wake Forest University that can be developed into CALGB protocols * To expand the Affiliate Network of the Comprehensive Cancer Center of Wake Forest University in order to provide improved care of the cancer patient through access to CALGB Cancer Clinical Trials * To provide a clinical trials mechanism by which minority populations can accrue to clinical trails; to improve their proportional participation in clinical trials research; and to develop specific strategies to address regional barriers to minority recruitment and retention in clinical research studies * To continue our participation as a funded Prevention Member Center
期刊论文(37)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1182/blood.v60.2.454.bloodjournal602454
发表时间: 1982-08
期刊: Blood
影响因子: 20.3
作者: [Jerome W. Yates;O. Glidewell;P. Wiernik;Cooper;D. Steinberg;H. Dosik;R. Levy;C. Hoagland;P. Henry;A. Gottlieb;C. Cornell;J. Berenberg;JL Hutchison;P. Raich;N. Nissen;R. Ellison;R. Frelick;G. James;G. Falkson;R. Silver;F. Haurani;Mark A. Green;E. Henderson;L. Leone;J. Holland]
通讯作者: Jerome W. Yates;O. Glidewell;P. Wiernik;Cooper;D. Steinberg;H. Dosik;R. Levy;C. Hoagland;P. Henry;A. Gottlieb;C. Cornell;J. Berenberg;JL Hutchison;P. Raich;N. Nissen;R. Ellison;R. Frelick;G. James;G. Falkson;R. Silver;F. Haurani;Mark A. Green;E. Henderson;L. Leone;J. Holland
A phase II study of recombinant interleukin-2 with or without recombinant interferon-beta in non-Hodgkin's lymphoma. A study of the Cancer and Leukemia Group B.
重组白细胞介素 2 联合或不联合重组干扰素 β 在非霍奇金淋巴瘤中的 II 期研究。
DOI: 10.1097/00002371-199208000-00006
发表时间: 1992
期刊: Journal of immunotherapy : official journal of the Society for Biological Therapy
影响因子: --
作者: [Duggan,DB, Santarelli,MT, Zamkoff,K, Lichtman,S, Ellerton,J, Cooper,R, Poiesz,B, Anderson,JR, Bloomfield,CD, Peterson,BA]
通讯作者: Peterson,BA
Response rate and survival in myeloma patients receiving prednisone alone.
单独接受泼尼松治疗的骨髓瘤患者的缓解率和生存率。
DOI: 10.1002/mpo.2950130502
发表时间: 1985
期刊: Medical and pediatric oncology
影响因子: --
作者: [McIntyre,OR, Pajak,TF, Kyle,RA, Cornwell3rd,GG, Leone,L]
通讯作者: Leone,L
Mood and clinical status in patients with multiple myeloma.
多发性骨髓瘤患者的情绪和临床状态。
DOI: 10.1200/jco.1991.9.12.2219
发表时间: 1991
期刊: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子: --
作者: [Silberfarb,PM, Anderson,KM, Rundle,AC, Holland,JC, Cooper,MR, McIntyre,OR]
通讯作者: McIntyre,OR
34
    CLINICAL TRIAL: SELENIUM AND VITAMIN E CANCER PREVENTION TRIAL (SELECT)
    CLINICAL TRIAL: SELENIUM AND VITAMIN E CANCER PREVENTION TRIAL (SELECT)
    SELENIUM AND VITAMIN E CANCER PREVENTION TRIAL (SELECT)
    DETECTION OF MDS USING FISH IN PRETRANSPLANT SAMPLES